|Videos|May 25, 2022
Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC
Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Lutetium Lu 177 vipivotide tetraxetan showed a median overall survival of 13.1 months in the French PSMA-REACH mCRPC cohort.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The top 5 OncLive TV videos of the week cover insights in endometrial cancer, mCRPC, germ cell tumors, melanoma, and HNSCC.
Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.
The FDA approved talazoparib plus enzalutamide for HRR-positive, metastatic androgen pathway modulation–naive or -sensitive prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5